BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · IEX Real-Time Price · USD
0.841
+0.011 (1.36%)
Jul 22, 2024, 9:56 AM EDT - Market open
BioLineRx Employees
BioLineRx had 79 employees as of December 31, 2023. The number of employees increased by 30 or 61.22% compared to the previous year.
Employees
79
Change (1Y)
30
Growth (1Y)
61.22%
Revenue / Employee
$147,532
Profits / Employee
-$622,127
Market Cap
66.35M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Burning Rock Biotech | 786 |
Prenetics Global | 324 |
Celularity | 225 |
Pro-Dex | 146 |
Precision BioSciences | 109 |
Eyenovia | 57 |
VSee Lab/iDoc Virtual Telehealth Solutions, Inc. | 40 |
Milestone Scientific | 17 |
BLRX News
- 7 weeks ago - BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) - PRNewsWire
- 7 weeks ago - BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - PRNewsWire
- 2 months ago - BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting - PRNewsWire
- 2 months ago - BioLineRx to Report First Quarter 2024 Results on May 28, 2024 - PRNewsWire
- 2 months ago - BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 2 months ago - BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 - PRNewsWire
- 3 months ago - BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting - PRNewsWire
- 3 months ago - BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement - PRNewsWire